Sandeep M. Menon, MD, PhD, MPH, MS

Dr. Sandeep Menon is a physician-scientist with a unique background in Medicine and Biostatistics (Applied Mathematics) with a track record of developing innovative drugs across multiple therapeutic areas from target selection through approval. Most recently he served as the Chief Development Officer at Alnylam, overseeing Clinical Development and Safety. At Alnylam, Dr. Menon oversaw end to end development and safety for all therapeutic areas, including Neurology, Cardiology, Metabolism, Ophthalmology, Oncology, Hematology and Rare Disease. Previously, Dr. Menon spent nearly 14 years at Pfizer, serving latterly as Senior Vice President, Early Clinical Development and Chief Scientific Officer, Biomedicine AI-Digital Sciences; and a member of the R&D leadership team. While at Pfizer, Dr. Menon led a multi-functional global team overseeing program delivery for all therapeutic areas including Oncology. Prior to joining Pfizer, he was part of the Clinical Development and Biostatistics group at Biogen, and before that served at ICON for 5 years.

Dr. Menon has extensive experience in end-to-end development with regulatory submissions – BLA, NDA, PMA, MAA and CFDA. He received his medical degree from Bangalore (Karnataka) University, India, and later completed his Masters in Epidemiology and Biostatistics from Boston University, his Masters in Translational Pharmacology at Ohio State University, his Ph.D. in Biostatistics at Boston University, and later did his Research Fellowship at Harvard Clinical Research Institute. He has published more than 70 scientific original publications and book chapters and co-authored/co-edited 8 books. He has received several awards for academics, teaching and research excellence and recently received the Distinguished Biostatistics Alumni Award from Boston University School of Public Health.